US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Franklin Genomic Advancements ETF

41.81

0.0000

Volume:64

Turnover:2.69K

Market Cap:31.35M

PE:- -

High:41.81

Open:41.81

Low:41.81

Close:41.81

52wk High:43.51

52wk Low:29.80

Shares:750.00K

Float Shares:750.00K

Volume Ratio:0.13

T/O Rate:0.01%

Dividend:0.14

Dividend Rate:0.34%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Guardant Health Shield Blood Test Wins Carelon Coverage for Colorectal Cancer Screening

Natera announces publication of new data in Blood Neoplasia on Signatera

CytoDyn Net Loss Widens to $42.7 Million in FY26

Is Ligand Pharmaceuticals (LGND) Undervalued On Its Conference Appearance?

Simply Wall St.

Does Guardant Health’s (GH) Patent Appeal Reshape Its Competitive Moat More Than Its Royalty Bill?

Simply Wall St.

Adaptive Biotechnologies Director Katey Einterz Owen Sells 9,615 Shares for $249,990

Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer

THOMSON REUTERS

Adaptive Biotechnologies (ADPT), Why Is It Getting Fresh Attention Now?

Simply Wall St.

ABL Diagnostics Calls Shareholder Vote on Move to Euronext Growth and Name Change

Natera and Angiex partner in tumor testing using Signatera

Natera Partners with Angiex to Use Signatera ctDNA Test in Agx101 Phase I Trial Monitoring

Natera, - Announces Signatera Collaboration with Angiox to Assess Nd-ADC Therapy Response

THOMSON REUTERS

Natera, - Collaboration Includes Longitudinal Signatera Ctdna Testing for Agx101 Response Monitoring

THOMSON REUTERS

Fujian Unveils Plans to Boost Cross-Strait Biotech and Medical Collaboration Zone

Ligand Targets $150-$250 Million in Annual Investments as Royalty Revenue Tops $225 Million in 2026 Guidance

Ligand Management Participates in Wells Fargo Healthcare Conference Fireside Chat

Unified Pathology Index Launches Nationwide, One Code Bridges Data Gaps for Precision Care

Court Win Over Natera Patents Could Be A Game Changer For NeoGenomics’ (NEO) RaDaR ST

Simply Wall St.

Guardant Health Co-CEO AmirAli Talasaz Disposes of USD 6.35 Million in Common Shares

Natera (NTRA) As Druckenmiller Backs Growth Story, Is The Valuation Already Priced In?

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/HELX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HELX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","market":"US","secType":"STK","nameCN":"Franklin Genomic Advancements ETF","latestPrice":41.805,"timestamp":1788281993669,"preClose":41.805,"halted":0,"volume":64,"delay":0,"changeRate":0,"floatShares":750000,"shares":750000,"eps":0,"marketStatus":"Trading","change":0,"latestTime":"09-01 13:05:14 EDT","open":41.805,"high":41.805,"low":41.805,"amount":2686.630848,"amplitude":0,"askPrice":42.07,"askSize":20,"bidPrice":41.95,"bidSize":600,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788292800000},"marketStatusCode":2,"adr":0,"exchange":"CBOE","adjPreClose":41.805,"sharesOutstanding":650000,"nav":42.107,"aum":31580133.13,"dividendRate":0.003399,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":41.812,"preClose":41.805,"latestTime":"19:30 EDT","volume":8,"amount":334.44,"timestamp":1788219002456,"change":0.007,"changeRate":0.000167,"amplitude":0},"volumeRatio":0.13359,"impliedVol":0.0655,"impliedVolPercentile":0.0635},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","floatShares":750000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.13359,"shares":750000,"dividePrice":0.1421,"high":41.805,"amplitude":0,"preClose":41.805,"low":41.805,"week52Low":29.8,"pbRate":"--","week52High":43.5089,"institutionHeld":0,"latestPrice":41.805,"committee":0.935484,"eps":0,"divideRate":0.003399,"volume":64,"delay":0,"ttmEps":0,"open":41.805,"prevYearClose":36.3062,"prevWeekClose":42.0768,"prevMonthClose":41.805,"prevQuarterClose":39.9651,"fiveDayClose":43.3608,"twentyDayClose":39.3001,"sixtyDayClose":35.7434},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HELX\",params:#limit:5,,,undefined,":[{"date":"2025-12-30","symbol":"HELX","amount":0.14334,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Franklin Genomic Advancements ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-08","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2026-01-08"},{"market":"US","date":"2021-12-30","symbol":"HELX","amount":0.003935,"defaultRemindTime":1640874600000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2022-01-07","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000},{"market":"US","date":"2021-12-13","symbol":"HELX","amount":0.114148,"defaultRemindTime":1639405800000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2021-12-21","payableDate":"2021-12-14","currency":"USD","type":"dividend","dateTimestamp":1639371600000},{"market":"US","date":"2020-12-14","symbol":"HELX","amount":0.005005,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2020-12-23","payableDate":"2020-12-15","currency":"USD","type":"dividend","dateTimestamp":1607922000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HELX\",market:\"US\",,,undefined,":[{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-23","value":0.005005,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-21","value":0.114148,"currency":"USD"},{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-07","value":0.003935,"currency":"USD"},{"executeDate":"2025-12-30","recordDate":"2025-12-30","paymentDate":"2026-01-08","value":0.14334,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HELX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HELX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664856780","title":"Guardant Health Shield Blood Test Wins Carelon Coverage for Colorectal Cancer Screening","url":"https://stock-news.laohu8.com/highlight/detail?id=2664856780","media":"Reuters","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664856780?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:06","pubTimestamp":1788264367,"startTime":"0","endTime":"0","summary":"Guardant Health Shield blood test wins Carelon coverage for colorectal cancer screeningGuardant Health secured Carelon Healthcare Services coverage for its FDA-approved Shield blood test for colorecta","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL9hPZ6Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","LU0109394709.USD","BK4588","GDOC","BK4196","GNMX","FFOX","HELX","LU0320765992.SGD","GNOM","BK4585","GH","LU0889565916.HKD","BK4551","BK4535","EKG","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664853895","title":"Natera announces publication of new data in Blood Neoplasia on Signatera","url":"https://stock-news.laohu8.com/highlight/detail?id=2664853895","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664853895?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:25","pubTimestamp":1788258359,"startTime":"0","endTime":"0","summary":"Natera (NTRA) announced the publication of new data in Blood Neoplasia, validating the prognostic and predictive value of Signatera in patients wit...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/natera-announces-publication-of-new-data-in-blood-neoplasia-on-signatera-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/natera-announces-publication-of-new-data-in-blood-neoplasia-on-signatera-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1064131342.USD","BK4139","LU0012050646.USD","LU1988902786.USD","LU2065170008.USD","GNOM","LU2065731478.USD","NTRA","LU2324357040.USD","LU0053671581.USD","LU2065169927.USD","HELX","LU0345770993.USD","LU2065171311.SGD","LU2264538146.SGD","LU2065171402.SGD","LU0106261612.USD","LU0345770308.USD","LU0963586101.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663039950","title":"CytoDyn Net Loss Widens to $42.7 Million in FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2663039950","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663039950?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:35","pubTimestamp":1788179703,"startTime":"0","endTime":"0","summary":"CytoDyn net loss widens to $42.7 million in FY26CytoDyn posted a net loss of $42.7 million, swinging from net income of $3.7 million a year earlier.Operating loss widened to $38.6 million as operating","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDLbc0jH6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065731478.USD","CYDY","LU0963586101.USD","LU2324357040.USD","LU2264538146.SGD","LU0012050646.USD","BK4139","LU0053671581.USD","LU2065171402.SGD","GNOM","LU0345770993.USD","LU1988902786.USD","LU2065170008.USD","LU0345770308.USD","NTRA","LU0106261612.USD","HELX","LU2065171311.SGD","LU1064131342.USD","LU2065169927.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663044806","title":"Is Ligand Pharmaceuticals (LGND) Undervalued On Its Conference Appearance?","url":"https://stock-news.laohu8.com/highlight/detail?id=2663044806","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663044806?lang=en_us&edition=fundamental","pubTime":"2026-08-30 19:23","pubTimestamp":1788089019,"startTime":"0","endTime":"0","summary":"Conference appearance puts focus on Ligand Pharmaceuticals stock\nLigand Pharmaceuticals (LGND) is set to present at the 17th Annual Midwest IDEAS Conference in Chicago on 26 August 2026 at 9:15 a.m., drawing attention to its business model and recent share performance.\nRecent trading has been slightly softer around the conference, with the share price down 1.42% over the past day and 2.45% over the past month. However, Ligand Pharmaceuticals still shows strong momentum with a 47.54% year to...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lgnd/ligand-pharmaceuticals/news/is-ligand-pharmaceuticals-lgnd-undervalued-on-its-conference","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lgnd/ligand-pharmaceuticals/news/is-ligand-pharmaceuticals-lgnd-undervalued-on-its-conference","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","BK4139","LU1559883803.SGD","HELX","LGND","LU0566484027.USD","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663044590","title":"Does Guardant Health’s (GH) Patent Appeal Reshape Its Competitive Moat More Than Its Royalty Bill?","url":"https://stock-news.laohu8.com/highlight/detail?id=2663044590","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663044590?lang=en_us&edition=fundamental","pubTime":"2026-08-30 19:19","pubTimestamp":1788088793,"startTime":"0","endTime":"0","summary":"In August 2026, Guardant Health said it would appeal a US District Court of Delaware final judgment in a patent dispute with TwinStrand Biosciences and the University of Washington, with execution of the judgment and collection of potential royalties paused during the appeal.\nThe court’s royalty order applies mainly to older Guardant tests, while Guardant reports that upgraded versions of key products such as Shield and Reveal, along with validated design changes to Guardant360, fall outside...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/does-guardant-healths-gh-patent-appeal-reshape-its-competiti","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/does-guardant-healths-gh-patent-appeal-reshape-its-competiti","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0109394709.USD","PTH","GDOC","BK4535","EKG","GNOM","FFOX","GNMX","BK4551","GH","BK4196","BK4585","LFSC","LU0889565916.HKD","BK4588","LU0320765992.SGD","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663168840","title":"Adaptive Biotechnologies Director Katey Einterz Owen Sells 9,615 Shares for $249,990","url":"https://stock-news.laohu8.com/highlight/detail?id=2663168840","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663168840?lang=en_us&edition=fundamental","pubTime":"2026-08-29 05:50","pubTimestamp":1787953835,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies director Katey Einterz Owen sells 9,615 shares for $249,990Adaptive Biotechnologies director Katey Einterz Owen sold 9,615 common shares on Aug. 26, 2026 at USD 26.Directly he","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDL80PDl0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotechnologies Director Katey Einterz Owen Sells 9,615 Shares for $249,990","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","HELX","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662594094","title":"Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2662594094","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662594094?lang=en_us&edition=fundamental","pubTime":"2026-08-28 23:03","pubTimestamp":1787929380,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nTUABNSJHG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2065171311.SGD","LU2065731478.USD","LU0963586101.USD","LU1064131342.USD","HELX","LU0345770993.USD","LU1988902786.USD","LU2065170008.USD","LU2065171402.SGD","LU0106261612.USD","NTRA","LU0345770308.USD","BK4139","LU2324357040.USD","LU2065169927.USD","LU0012050646.USD","GNOM","LU2264538146.SGD","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662055660","title":"Adaptive Biotechnologies (ADPT), Why Is It Getting Fresh Attention Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2662055660","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662055660?lang=en_us&edition=fundamental","pubTime":"2026-08-28 11:26","pubTimestamp":1787887617,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies (ADPT) has drawn fresh investor attention after its recent share price performance, with the stock last closing at $26.44. The move puts a spotlight on how the company’s immune medicine platform and cancer diagnostics business are currently valued.\nFor context, Adaptive Biotechnologies has shown strong momentum recently, with a 17.41% 1 month share price return, a 74.52% 3 month share price return and a 98.65% 1 year total shareholder return. Together, these figures...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/adaptive-biotechnologies-adpt-why-is-it-getting-fresh-attent","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/adaptive-biotechnologies-adpt-why-is-it-getting-fresh-attent","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4121","ADPT","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662084970","title":"ABL Diagnostics Calls Shareholder Vote on Move to Euronext Growth and Name Change","url":"https://stock-news.laohu8.com/highlight/detail?id=2662084970","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662084970?lang=en_us&edition=fundamental","pubTime":"2026-08-28 00:37","pubTimestamp":1787848643,"startTime":"0","endTime":"0","summary":"An update from ABL Diagnostics SA ( ($FR:ABLD) ) is now available. ABL Diagnostics SA, a publicly listed French molecular diagnostics group, provid...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/abl-diagnostics-calls-shareholder-vote-on-move-to-euronext-growth-and-name-change?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/abl-diagnostics-calls-shareholder-vote-on-move-to-euronext-growth-and-name-change?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNMX","ABLD","HELX","BMED","HTEC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662221703","title":"Natera and Angiex partner in tumor testing using Signatera","url":"https://stock-news.laohu8.com/highlight/detail?id=2662221703","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662221703?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:10","pubTimestamp":1787825446,"startTime":"0","endTime":"0","summary":"Natera (NTRA) announced a new Signatera collaboration with Angiex, a privately held biotech company developing a portfolio of Nuclear-Delivered Ant...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/natera-and-angiex-partner-in-tumor-testing-using-signatera-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/natera-and-angiex-partner-in-tumor-testing-using-signatera-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065171402.SGD","XBIX","LU2324357040.USD","LU0963586101.USD","LU2065169927.USD","LU0012050646.USD","LU1988902786.USD","HELX","NTRA","BK4139","LU0345770308.USD","LU0106261612.USD","LU1064131342.USD","LU0345770993.USD","LU2264538146.SGD","GNOM","LU0053671581.USD","LU2065731478.USD","NVIB","LU2065171311.SGD","LU2065170008.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662370845","title":"Natera Partners with Angiex to Use Signatera ctDNA Test in Agx101 Phase I Trial Monitoring","url":"https://stock-news.laohu8.com/highlight/detail?id=2662370845","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662370845?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:01","pubTimestamp":1787824870,"startTime":"0","endTime":"0","summary":"Natera partners with Angiex to use Signatera ctDNA test in AGX101 Phase I trial monitoringNatera entered a Signatera collaboration with Angiex to track treatment response in Angiex’s Phase I AGX101 so","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL4FwL4F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345770308.USD","LU2065171402.SGD","LU2065731478.USD","LU0012050646.USD","LU0106261612.USD","LU0053671581.USD","LU1988902786.USD","LU2065171311.SGD","GNOM","LU1064131342.USD","NTRA","BK4139","LU2324357040.USD","LU2065170008.USD","LU2264538146.SGD","LU0345770993.USD","LU2065169927.USD","HELX","LU0963586101.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662708626","title":"Natera, - Announces Signatera Collaboration with Angiox to Assess Nd-ADC Therapy Response","url":"https://stock-news.laohu8.com/highlight/detail?id=2662708626","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662708626?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:00","pubTimestamp":1787824827,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O0RC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2264538146.SGD","BK4139","LU2065170008.USD","LU0012050646.USD","LU2065171402.SGD","LU0345770308.USD","HELX","LU0053671581.USD","LU0963586101.USD","LU0106261612.USD","LU2065169927.USD","LU1064131342.USD","LU2065171311.SGD","GNOM","LU2324357040.USD","LU0345770993.USD","LU2065731478.USD","NTRA","LU1988902786.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662708603","title":"Natera, - Collaboration Includes Longitudinal Signatera Ctdna Testing for Agx101 Response Monitoring","url":"https://stock-news.laohu8.com/highlight/detail?id=2662708603","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662708603?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:00","pubTimestamp":1787824827,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O0RC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0963586101.USD","LU2065731478.USD","NTRA","LU2065171402.SGD","LU0053671581.USD","LU1988902786.USD","LU2324357040.USD","HELX","LU2264538146.SGD","LU0012050646.USD","LU1064131342.USD","LU2065170008.USD","LU2065171311.SGD","GNOM","LU2065169927.USD","LU0106261612.USD","BK4139","LU0345770993.USD","LU0345770308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158123171","title":"Fujian Unveils Plans to Boost Cross-Strait Biotech and Medical Collaboration Zone","url":"https://stock-news.laohu8.com/highlight/detail?id=1158123171","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158123171?lang=en_us&edition=fundamental","pubTime":"2026-08-27 15:00","pubTimestamp":1787814046,"startTime":"0","endTime":"0","summary":"On August 27, the \"15th Five-Year Plan for Health Development in Fujian Province\" was officially released, outlining key initiatives for the upcoming period.Among the highlighted measures, the plan...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","XLV","VHT","WDNA","BK4581","BK4585","BK4588","XBI","IXJ","BK4550","HELX","159760"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662109537","title":"Ligand Targets $150-$250 Million in Annual Investments as Royalty Revenue Tops $225 Million in 2026 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2662109537","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662109537?lang=en_us&edition=fundamental","pubTime":"2026-08-26 22:27","pubTimestamp":1787754449,"startTime":"0","endTime":"0","summary":"Ligand targets $150-$250 million in annual investments as royalty revenue tops $225 million in 2026 guidanceLigand guided to 2026 adjusted EPS of $9-$9.5 on total revenue of $270-$310 million.Royalty ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL5nSN5c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGND","BK4139","LU1559883803.SGD","LU0566484027.USD","IE0009354923.USD","HELX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662046718","title":"Ligand Management Participates in Wells Fargo Healthcare Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2662046718","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662046718?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:02","pubTimestamp":1787742166,"startTime":"0","endTime":"0","summary":"Ligand management participates in Wells Fargo Healthcare Conference fireside chatLigand management will appear at three investor conferences in September 2026, including two fireside chats, one presen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL7TCS5F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0162691827.USD","LU0980610538.SGD","IE00BKPKM429.USD","LU2236285917.USD","LU1144417596.USD","LU1267930227.SGD","LU1506573853.SGD","TFNS","LU0098860793.USD","LU1559883803.SGD","BCDF","IE00B3QW5Z07.USD","LU1074936037.SGD","HELX","LU2095319765.USD","LU2210150020.SGD","IE00BN0W2T93.GBP","LU0203347892.USD","LU1791807156.HKD","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","FTXO","NDAQ","LU0170899867.USD","LU0648001328.SGD","IE00BQXX3F31.USD","BK4559","LU0314106906.USD","LU0477156953.USD","BK4566","LU2417539215.USD","LU0128525689.USD","LU0314104364.USD","LU2360032135.SGD","SG9999014021.USD","IE00BQXX3C00.GBP","LU0130102774.USD","IE00BSNM7G36.USD","IE0009354923.USD","LU0106831901.USD","LU1201861249.SGD","IYF","LU1244550494.USD","BK4585","LU0130517989.USD","LU1244550577.SGD","LU1366192091.USD","LU2456880835.USD","LU0203345920.USD","LGND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180152997","title":"Unified Pathology Index Launches Nationwide, One Code Bridges Data Gaps for Precision Care","url":"https://stock-news.laohu8.com/highlight/detail?id=1180152997","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180152997?lang=en_us&edition=fundamental","pubTime":"2026-08-26 11:36","pubTimestamp":1787715362,"startTime":"0","endTime":"0","summary":"On August 14, 2026, the National Healthcare Security Administration officially issued the coding standard for the Medical Insurance Pathology Cloud Index, marking another milestone in digital...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WDNA","GNMX","HTEC","XT","BMED","DTEC","GNOM","SYNB","HELX","TYNE","KOMP","IDNA","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662757992","title":"Court Win Over Natera Patents Could Be A Game Changer For NeoGenomics’ (NEO) RaDaR ST","url":"https://stock-news.laohu8.com/highlight/detail?id=2662757992","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662757992?lang=en_us&edition=fundamental","pubTime":"2026-08-26 03:24","pubTimestamp":1787685840,"startTime":"0","endTime":"0","summary":"NeoGenomics, Inc. previously announced that Alicia Olivo, EVP, General Counsel & Business Development, would step down as General Counsel in September 2026 and remain with the company until early October 2026 to support the transition.\nThe company also secured a favorable North Carolina court ruling that invalidated key Natera patents, reducing legal friction around its RaDaR ST assay and altering the competitive landscape in molecular residual disease testing.\nWe’ll now examine how this...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-neo/neogenomics/news/court-win-over-natera-patents-could-be-a-game-changer-for-ne","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-neo/neogenomics/news/court-win-over-natera-patents-could-be-a-game-changer-for-ne","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2065169927.USD","LU1064131342.USD","LU2065171402.SGD","LU0345770308.USD","LU2065731478.USD","LU0106261612.USD","LU0053671581.USD","NEO","BK4121","LU0012050646.USD","LU2264538146.SGD","BK4139","LU0345770993.USD","LU2065171311.SGD","GNOM","LU1988902786.USD","FBT","LU0963586101.USD","NTRA","LU2324357040.USD","LU2065170008.USD","HELX","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662020952","title":"Guardant Health Co-CEO AmirAli Talasaz Disposes of USD 6.35 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2662020952","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662020952?lang=en_us&edition=fundamental","pubTime":"2026-08-25 05:22","pubTimestamp":1787606549,"startTime":"0","endTime":"0","summary":"Guardant Health Co-CEO AmirAli Talasaz disposes of USD 6.35 million in common sharesGuardant Health Co-CEO AmirAli Talasaz sold 37,500 common shares on Aug. 21, 2026 through the Talasaz Family Foundat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL9NSL6W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health Co-CEO AmirAli Talasaz Disposes of USD 6.35 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","GNOM","GDOC","BK4535","BK4551","LU0320765992.SGD","PTH","EKG","GH","BK4196","GNMX","LU0109394709.USD","BK4585","LU0889565916.HKD","HELX","FFOX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662209693","title":"Natera (NTRA) As Druckenmiller Backs Growth Story, Is The Valuation Already Priced In?","url":"https://stock-news.laohu8.com/highlight/detail?id=2662209693","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662209693?lang=en_us&edition=fundamental","pubTime":"2026-08-25 04:23","pubTimestamp":1787603037,"startTime":"0","endTime":"0","summary":"Natera (NTRA) is back on investor radar after Stanley Druckenmiller's family office made the stock its largest holding. This coincides with strong revenue growth, higher test volumes, and improving free cash flow.\nSee our latest analysis for Natera.\nNatera’s recent news on clinical collaborations and higher test volumes sits alongside strong momentum in the stock. The 30 day share price return of 26.73% and 1 year total shareholder return of 104.36% point to building enthusiasm, while the...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/natera-ntra-as-druckenmiller-backs-growth-story-is-the-valua","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/natera-ntra-as-druckenmiller-backs-growth-story-is-the-valua","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","HELX","LU2065169927.USD","LU1064131342.USD","LU1988902786.USD","DCF","LU2324357040.USD","LU0963586101.USD","LU2065171311.SGD","LU2065171402.SGD","NTRA","LU0345770308.USD","LU0106261612.USD","LU2264538146.SGD","LU0345770993.USD","GNOM","LU0012050646.USD","LU2065170008.USD","LU0053671581.USD","LU2065731478.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}